Clinical trials: Crisis State
Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL
An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®
This is an observational registry to further characterize the safety profile of patients with chronic myeloid leukemia in the chronic phase (CP-CML), accelerated phase (AP-CML), blast phase (BP-CML), or Ph+ALL treated with…
- Trial name
- OMNI (NCT02455024)
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Ariad Pharmaceuticals